| Literature DB >> 29361949 |
Man-Qing Cao1,2, A-Bin You3, Xiao-Dong Zhu1, Wei Zhang2, Yuan-Yuan Zhang1, Shi-Zhe Zhang1, Ke-Wei Zhang4, Hao Cai1, Wen-Kai Shi1, Xiao-Long Li1, Kang-Shuai Li1, Dong-Mei Gao1, De-Ning Ma5, Bo-Gen Ye6, Cheng-Hao Wang7, Cheng-Dong Qin8, Hui-Chuan Sun9, Ti Zhang10, Zhao-You Tang11.
Abstract
BACKGROUND: High frequency of recurrence is the major cause of the poor outcomes for patients with hepatocellular carcinoma (HCC). microRNA (miR)-182-5p emerged as a high-priority miRNA in HCC and was found to be related to HCC metastasis. Whether the expression of miR-182-5p in tumor tissue correlated with early recurrence in HCC patients underwent curative surgery was unknown.Entities:
Keywords: FOXO3a; HCC; Wnt signaling; miR-182-5p
Mesh:
Substances:
Year: 2018 PMID: 29361949 PMCID: PMC5782375 DOI: 10.1186/s13045-018-0555-y
Source DB: PubMed Journal: J Hematol Oncol ISSN: 1756-8722 Impact factor: 17.388
Fig. 1miR182-5p can be regarded as predictor for early recurrence of HCC. a Relative expression of miR-182-5p in different HCC cell lines. b Relative expression of miR-182-5p in HCC and adjacent tissues of GEO database (GSE22058). c Relative miR-182-5p expression in paired HCC tissues and adjacent tissues. d The relationship between expression of miR-182-5p and overall survival of HCC patients in TCGA database. e ISH staining of U6 and miR-182-5p in HCC and adjacent tissues. f The relationship between expression of miR-182-5p and recurrence-free survival of HCC patients in Zhongshan hospital. (*P < 0.05, **P < 0.01, ***P < 0.001)
Correlation between miR-182-5p expression and HCC clinicopathological parameters
| Parameters |
| miR-182-5p | ||
|---|---|---|---|---|
| Low ( | High ( | |||
| Gender | ||||
| Male | 100 | 66 | 34 | 0.602 |
| Female | 19 | 14 | 5 | |
| Age (years) | ||||
| < 50 | 30 | 18 | 12 | 0.372 |
| ≥ 50 | 89 | 62 | 27 | |
| Cirrhosis | ||||
| Absence | 27 | 22 | 5 | 0.102 |
| Presence | 92 | 58 | 34 | |
| Tumor number | ||||
| Single | 96 | 66 | 30 | 0.471 |
| Multiple | 23 | 14 | 9 | |
| Tumor size(cm) | ||||
| < 5 cm | 102 | 70 | 32 | 0.418 |
| ≥ 5 | 17 | 10 | 7 | |
| Micro vein invasion | ||||
| Absence | 77 | 54 | 23 | 0.416 |
| Presence | 42 | 26 | 16 | |
| HBV infection | ||||
| Absence | 16 | 13 | 3 | 0.259 |
| Presence | 103 | 67 | 36 | |
| AFP | ||||
| < 20 | 54 | 42 | 12 | 0.031* |
| ≥ 20 | 65 | 38 | 27 | |
AFP alpha-fetoprotein
*P < 0.05
Univariate analyses of prognostic factors for recurrence-free survivals
| Parameters |
| Chi-square | |
|---|---|---|---|
| Gender | 0.084 | 0.772 | |
| Male | 100 | ||
| Female | 19 | ||
| Age | 0.009 | 0.924 | |
| < 50 | 30 | ||
| ≥ 50 | 89 | ||
| Cirrhosis | 0.732 | 0.392 | |
| Absence | 27 | ||
| Presence | 92 | ||
| Staining intensity | 6.728 | 0.009* | |
| Low | 80 | ||
| High | 39 | ||
| Tumor number | 1.177 | 0.278 | |
| Single | 96 | ||
| Multiple | 23 | ||
| Tumor size | 0.000 | 0.986 | |
| < 5 cm | 102 | ||
| ≥ 5 | 17 | ||
| Micro vein invasion | 4.809 | 0.028* | |
| Absence | 77 | ||
| Presence | 42 | ||
| HBV infection | 0.861 | 0.353 | |
| Absence | 16 | ||
| Presence | 103 | ||
| AFP | 5.859 | 0.015* | |
| < 20 | 54 | ||
| ≥ 20 | 65 |
*P < 0.05
Multivariate analyses of prognostic factors for recurrence-free survivals
| Parameters | B | SE | Exp(B) | |
|---|---|---|---|---|
| Staining intensity | − 0.713 | 0.341 | 0.036* | 0.490 |
| Micro vein invasion | 0.554 | 0.345 | 0.108 | 1.740 |
| AFP | 0.592 | 0.382 | 0.121 | 1.808 |
*P < 0.05
Fig. 2Effects of miR182-5p in HCC proliferation and invasion. a Relative miR-182-5p expression in HCC cells that overexpressed miR-182-5p in MHCC-97H cells and knockdown miR-182-5p in MHCC-97L cells. b CCK8 assays of miR-NC cells and miR-182-5p-overexpression cells of MHCC-97H, and CCK8 assays of Anti-NC cells and miR-182-5p-inhibition cells of MHCC-97L cells. c Transwell assays of miR-NC cells and miR-182-5p-overexpression cells of MHCC-97H, and transwell assays of anti-NC cells and miR-182-5p-inhibition cells of MHCC-97L cells. (*P < 0.05, **P < 0.01, ***P < 0.001)
Fig. 3The role of miR-182-5p in HCC growth and lung metastasis. a Orthotopic transplantation tumor formation with miR-NC and miR-182-5p overexpression in MHCC-97H cells, and tumor size analysis of the miR-NC and miR-182-5p overexpression groups. b Orthotopic transplantation tumor formation with anti-NC and miR-182-5p inhibition in MHCC-97L cells, and tumor size analysis of the anti-NC and miR-182-5p inhibition groups. c The images of lung metastasis of miR-NC and miR-182-5p-overexpression groups by stereo fluorescence microscope and lung metastasis analysis of miR-NC and miR-182-5p-overexpression groups. d The images of lung metastasis of anti-NC and miR-182-5p-inhibiton groups by stereo fluorescence microscope, and lung metastasis analysis of anti-NC and miR-182-5p-inhibition groups. (*P < 0.05, **P < 0.01, ***P < 0.001)
Fig. 4miR-182-5p targets FOXO3a to activate AKT pathway. a Predicted binding sites of 3′-UTR of FOXO3a to miR-182-5p, and the relative Rluc/Luc ratio of dual-luciferase reporter assay in different groups. b Western blot analysis of AKT/FOXO3a signaling-related proteins in control group, overexpression and knockdown miR-182-5p group of HCC cells. c Western blot analysis of p-AKT Ser473 expression after FOXO3a knockdown. d FASC analysis of cell apoptosis rate in miR-NC and miR-182-5p overexpression cells
Fig. 5FOXO3a exerts an important mediator in miR-182-5p induced Wnt signaling activation. a Western blot analysis of Wnt signaling pathway related proteins following miR-182-5p overexpression and knockdown. b IHC staining of FOXO3a and β-catenin in orthotopic tumor tissues of negative control and overexpression of miR-182-5p. c Western blot analysis of c-Myc in miR-NC cells treated with different concentration of XAV939 (0, 1, 5, 10, 100, and 200 μM). d Transwell assay of HCC cells that transfected with miR-NC, overexpression of miR-182-5p and miR-182-5p overexpression cells that further treated with 10 μM XAV939. e Western blot analysis of Wnt signaling pathway-related proteins in miR-NC cells, overexpression of miR-182-5p cells and miR-182-5p overexpression cells further overexpress FOXO3a
Fig. 6miR-182-5p inhibits β-catenin degradation and enhances the binding of β-catenin/TCF4. a Western blot analysis of β-catenin expression in miR-NC and miR-182-5p overexpression cells that treated with 100 μg/mL CHX at 0, 1.5, and 3 h. b Endogenous TCF4 was immunoprecipitated, and binding of β-catenin to TCF4 was analyzed by immunoblotting for β-catenin. c Endogenous FOXO3a was immunoprecipitated, and binding of β-catenin to FOXO3a was analyzed by immunoblotting for β-catenin